Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-25-000089
Filing Date
2025-11-05
Accepted
2025-11-05 16:05:10
Documents
68
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20250930.htm   iXBRL 10-Q 1369921
2 EX-31.1 exhibit311q32025.htm EX-31.1 17235
3 EX-31.2 exhibit312q32025.htm EX-31.2 17116
4 EX-32.1 exhibit321q32025.htm EX-32.1 9852
  Complete submission text file 0001664710-25-000089.txt   6037924

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250930.xsd EX-101.SCH 41059
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20250930_cal.xml EX-101.CAL 53139
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20250930_def.xml EX-101.DEF 255362
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250930_lab.xml EX-101.LAB 551006
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250930_pre.xml EX-101.PRE 388092
71 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250930_htm.xml XML 613383
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 251453846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)